Market capitalization | $370.44m |
Enterprise Value | $221.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.96 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-48.48m |
Free Cash Flow (TTM) Free Cash Flow | $-39.96m |
Cash position | $150.04m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a GH Research PLC forecast:
6 Analysts have issued a GH Research PLC forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.32 -0.32 |
28%
28%
|
|
EBITDA | -48 -48 |
24%
24%
|
EBIT (Operating Income) EBIT | -48 -48 |
24%
24%
|
Net Profit | -41 -41 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Villy Valcheva |
Employees | 49 |
Founded | 2021 |
Website | www.ghres.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.